← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › ANTIGOUT PREPARATIONS › ANTIGOUT PREPARATIONS › Other antigout preparations
urate oxidase
M04AX01
Forms & Strengths
- Powder for reconstitution: 1.5 mg per vial
- Solution for injection/infusion: 2 mg/vial
Adult Dosing
- 0.2 mg/kg IV once daily for up to 5 days for the management of plasma uric acid levels in patients at risk for tumor lysis syndrome
- Administer infusion over approximately 30 minutes
Pediatric Dosing
- 0.2 mg/kg IV once daily for up to 5 days in pediatric patients aged 1 month to 17 years at risk for hyperuricemia associated with malignancy
- Same dosing regimen and administration duration as adults
Indications
- Initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent hyperuricemia
Mechanism of Action
- Recombinant urate-oxidase enzyme that catalyzes the enzymatic oxidation of uric acid into an inactive and soluble metabolite (allantoin)
- Reduces serum uric acid levels rapidly, preventing uric acid-induced acute renal failure
Contraindications
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency
- History of anaphylaxis or severe hypersensitivity to urate oxidase or pegylated urate oxidase
- History of hemolytic reactions associated with urate oxidase
- Methemoglobinemia-associated adverse events
Adverse Reactions
- Anaphylaxis and severe hypersensitivity reactions
- Hemolysis in patients with G6PD deficiency
- Methemoglobinemia
- Nausea, vomiting, diarrhea, and headache
- Fever and rash
Drug Interactions
- No formal drug interaction studies have been conducted
- Concomitant use with other agents that affect uric acid levels may alter pharmacodynamic response
- Interferes with in vitro uric acid assays if blood samples are not handled on ice and analyzed promptly
Curated Content: Needs Vetting Before Put to Clinical Use